Genetic testing

NASA Nurtures Promising Tech Ideas from Small Businesses

Retrieved on: 
Monday, April 22, 2024
Transfer, Small business, Partnership, Small Business Innovation Research, Moon, STMD, NASA, Workload, Life, Ames Research Center, STTR, Genetic testing, NASA Headquarters, Human, DNA, Silicon, Multimedia, SBIR, Artemis, Atmosphere, Communications satellite

Specifically, NASA's SBIR program awarded $93.5 million in Phase II contracts to bring 107 new ideas to life from 95 selected small businesses.

Key Points: 
  • Specifically, NASA's SBIR program awarded $93.5 million in Phase II contracts to bring 107 new ideas to life from 95 selected small businesses.
  • For example, NASA selected women-owned and first-time NASA Phase II awardee nou Systems, Inc. in Huntsville, Alabama, for its genetic testing instrument.
  • "Our program works directly with small businesses to forge innovative concepts and technologies that drive impact for NASA projects as well as a myriad of commercial endeavors," said Jason L. Kessler, program executive for NASA's SBIR and Small Business Technology Transfer (STTR) program at NASA Headquarters.
  • The NASA SBIR program is open to U.S. small businesses to develop an innovation or technology.

Invitae Publishes its Environmental, Social and Governance (ESG) Report

Retrieved on: 
Monday, April 22, 2024
FDA, Social, Food and Drug Administration, Food, Uncertainty, OTC, Environmental policy, Machine learning, Biophysical environment, Genetic testing, Environment, DNA, Patient, Classification, ESG, Medicine, Cancer, Drug discovery, Pharmaceutical industry

SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year.

Key Points: 
  • – Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 –
    SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report.
  • "At Invitae, sustainability isn't just a function; it's woven into the very fabric of our DNA.
  • We've embraced sustainability and ESG as catalysts for transformative change," said Erik Kaiser, chief sustainability officer of Invitae.
  • The report provides an in-depth review of the progress made in the past year through company-wide ESG initiatives.

Ascential Medical & Life Sciences Appoints Anupam Girdhar as Divisional CEO

Retrieved on: 
Tuesday, April 16, 2024
NACS, Genetic, Ideation, Baxter International, Automation, Thermo Fisher Scientific, Marketing, Clinical nutrition, Genetic testing, Ascential, Organization, Growth, Engineering, Management

SAN DIEGO, April 16, 2024 /PRNewswire/ -- Ascential Medical & Life Sciences today announced the appointment of Anupam Girdhar as divisional CEO. A business leader with 25 years of operational and strategic experience, Mr. Girdhar has managed complex life science tools and medical devices businesses. He has a proven track record fostering growth and cultivating top-tier organizations and will work towards positioning Ascential Medical & Life Sciences for lasting success.

Key Points: 
  • With more than two decades of relevant experience, Girdhar has held leadership positions at Thermo Fisher Scientific and Baxter Healthcare
    SAN DIEGO, April 16, 2024 /PRNewswire/ -- Ascential Medical & Life Sciences today announced the appointment of Anupam Girdhar as divisional CEO.
  • He has a proven track record fostering growth and cultivating top-tier organizations and will work towards positioning Ascential Medical & Life Sciences for lasting success.
  • "Anupam has an impressive background that combines technical and business expertise and a proven reputation in the medical and life sciences industry," said Jeff Moss, CEO of Ascential Technologies.
  • Ascential Medical & Life Sciences provides end-to-end capabilities for complex medical device assembly and total commercialization services from ideation to scaled manufacturing.

Multicancer Screening Market Projected to Reach $2.72 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Tuesday, April 16, 2024
FDA, Cancer, Genetics, Prostate, Saliva, Safety, Blood, AI, Food, Colorectal cancer, Machine learning, Breast, PET, Table, Artificial intelligence, Genetic testing, CLIA, Intelligence, Helmy Eltoukhy, Patient, MRI, Lung, Health, Diagnosis, Government, Quality of life, Algorithm, Growth, Liquid biopsy, Medical imaging

Meanwhile, countries such as India are beginning to embrace multi-cancer screening, buoyed by government efforts and innovations to create accessible healthcare solutions.

Key Points: 
  • Meanwhile, countries such as India are beginning to embrace multi-cancer screening, buoyed by government efforts and innovations to create accessible healthcare solutions.
  • Strategic collaborations among tech innovators, medical professionals, and regulatory bodies are essential to utilize the full potential of multi-cancer screening technologies.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Multicancer Screening Market.
  • "Dive into the Multicancer Screening Market Landscape: Explore 184 Pages of Insights, 580 Tables, and 26 Figures"

Multicancer Screening Market Projected to Reach $2.72 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Tuesday, April 16, 2024
FDA, Cancer, Genetics, Prostate, Saliva, Safety, Blood, AI, Food, Colorectal cancer, Machine learning, Breast, PET, Table, Artificial intelligence, Genetic testing, CLIA, Intelligence, Helmy Eltoukhy, Patient, MRI, Lung, Health, Diagnosis, Government, Quality of life, Algorithm, Growth, Liquid biopsy, Medical imaging

Meanwhile, countries such as India are beginning to embrace multi-cancer screening, buoyed by government efforts and innovations to create accessible healthcare solutions.

Key Points: 
  • Meanwhile, countries such as India are beginning to embrace multi-cancer screening, buoyed by government efforts and innovations to create accessible healthcare solutions.
  • Strategic collaborations among tech innovators, medical professionals, and regulatory bodies are essential to utilize the full potential of multi-cancer screening technologies.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Multicancer Screening Market.
  • "Dive into the Multicancer Screening Market Landscape: Explore 184 Pages of Insights, 580 Tables, and 26 Figures"

Synapticure and the ALS Association Partner to Expand Telehealth Access for People Living with ALS Nationwide

Retrieved on: 
Monday, April 15, 2024
Telehealth, Geography, Travel, ALS Association, Partnership, Genetic testing, Neurology, Speech, Senior counsel, Patient, Caregiver, ALS, Tourism

CHICAGO, April 15, 2024 /PRNewswire/ -- Synapticure, a leading telemedicine company focused on improving the lives of people and caregivers living with neurodegenerative diseases, and the ALS Association, the leading organization fighting ALS, announced a new partnership to expand access to quality care for people living with ALS across the United States.

Key Points: 
  • This will be particularly beneficial for people living with ALS in geographically remote areas who may struggle to access specialized multidisciplinary care.
  • "We are thrilled to partner with Synapticure to offer this innovative telehealth solution to people living with ALS nationwide.
  • As part of this collaboration, the ALS Association will provide people living with ALS access to both local and national resources.
  • Enhanced support network: Through this partnership, people living with ALS will have access to a wider network of healthcare professionals and resources.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
Friday, April 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Retrieved on: 
Thursday, April 11, 2024
Breast cancer, VUS, Medical school, Patient, Oncogenomics, Laboratory, OTC, FACMG, Machine learning, Research, Health, REA, Genetic testing, Black, DSM-IV codes, Classification, Society, Cancer, Algorithm, SAN, Gene

SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.

Key Points: 
  • The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.
  • After validating gene-specific machine learning algorithms, the impact on variant classification was analyzed in patients with breast cancer who underwent hereditary cancer genetic testing from January 2022 - May 2023.
  • Results offer reassurance that variants of uncertain significance in genetic testing results among breast cancer patients do not lead to overuse of breast surgeries, like mastectomies.
  • This study titled, "Real-World Breast Surgery Utilization among Breast Cancer Patients with Germline Variants of Uncertain Significance," examines breast surgery uptake in a large, recent sample of breast cancer patients undergoing genetic testing.

ACMG Foundation for Genetic and Genomic Medicine Elects Four Highly Accomplished Medical Genetics Professionals to its Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Education, Disorder, Rady Children's Hospital, Entrepreneurship, Doctor of Philosophy, Pathology, ACMG, Medical director, American Academy, Veterinarian, Myriad Genetics, FACMG, Drug, Genetic testing, Baylor College of Medicine, Distinguishing, International HapMap Project, New York University, Clinical Pediatrics, National academy, Hospital, Hispanic, Book, Health, American Medical Association, Research, Pediatrics (journal), Mental health, Master of Science, Genetic distance, Pediatrics, Women's health, School, Washington State University, Society, Cancer, Partnership, Genomics, American College, Policy, Genetic, Disability studies, Developmental Biology (journal), Friends, Patient, MED, MBA, Baylor University

The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.

Key Points: 
  • The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.
  • The board members are active participants, serving as advocates for the ACMG Foundation and for advancing its policies and programs.
  • ACMG Foundation President Nancy J. Mendelsohn, MD, FACMG said, "We are pleased to welcome these four new members to the ACMG Foundation Board of Directors.
  • "I am honored for the opportunity to serve the ACMG again through participation in the Foundation Board of Directors.

NCCN 2024 Annual Conference Shares Cancer Care Updates for Practical, Immediate Use in Practice

Retrieved on: 
Thursday, April 11, 2024
Maker, Congress, University, Cancer, NCCN, Risk, Policy, National Comprehensive Cancer Network, Hereditary nonpolyposis colorectal cancer, MD, Conference, BCPS, Research, University of Utah Hospital, Genetic testing, Patient, Doctor of Pharmacy, Physician, Caregiver, MBA, MHA, Pharmacist, Nursing

PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7. The yearly meeting includes opportunities for care providers to interact with world-renowned specialists on the latest evidence-based expert consensus recommendations for delivering high quality, patient-centered cancer care. Sessions focused on practical applications for improving care at every level, including clinical and administrative tracks, patient perspectives, and pressing policy issues.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7.
  • It includes both the clinical and administrative aspects of cancer care delivery; practical things to apply immediately.
  • "Clinical practice guidelines and continuing education events such as NCCN's Annual Conference democratize care and disseminate knowledge.
  • Other sessions delved into the latest updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for numerous cancer types, including: